Tocilizumab and COVID-19: Timing of administration assessment

被引：3

作者：

Richier, Q. ^{[1
]}

Jachiet, V ^{[2
]}

Bonnemains, V ^{[2
]}

Placais, L. ^{[3
]}

Abisror, N. ^{[2
]}

Garnier, M. ^{[4
]}

Pacanowski, J. ^{[1
]}

Dhote, R. ^{[5
]}

Hinchschberger, O. ^{[6
]}

Michel, M. ^{[7
]}

Bienvenu, B. ^{[8
]}

Comarmond, C. ^{[9
]}

Lacombe, K. ^{[1
]}

Mekinian, A. ^{[2
]}

机构：

[1] Sorbonne Univ, Hop St Antoine, AP HP, Serv Malad Infect,Inserm IPLESP, F-75012 Paris, France

[2] Sorbonne Univ, Hop St Antoine, AP HP, Serv Med Interne & Inflammat Immunopathol Biother, F-75012 Paris, France

[3] Hop Bicetre, AP HP, Serv Med Interne & Immunol Clin, Paris, France

[4] Sorbonne Univ, Hop St Antoine, AP HP,GRC 29, Serv Anesthesie Reanimat & Med Peri Operatoire, Paris, France

[5] Hop Avicenne, AP HP, Serv Med Interne, Paris, France

[6] Hop Emile Muller, Serv Med Interne, Mulhouse, France

[7] Hop Henri Mondor, AP HP, Serv Med Interne, Paris, France

[8] Hop St Joseph, Serv Med Interne, Marseille, France

[9] Hop La Pitie Salpetriere, AP HP, Serv Med Interne & Immunol Clin, Paris, France

来源：

INFECTIOUS DISEASES NOW | 2022年 / 52卷 / 01期

关键词：

COVID-19; Oxygen level; SARS-CoV-2; Timing of administration; Tocilizumab;

D O I：

10.1016/j.idnow.2021.06.304

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no association between the timing of injection after symptom onset and the efficacy of TCZ on mortality. We then investigated whether the oxygen level at the time of TCZ injection impacted the mortality rate. Our study finally suggested that TCZ could be less effective when oxygen requirement is > 11 L/min and we hypothesized that earlier administration could be associated with better outcome. However, randomized clinical trials are required to confirm this hypothesis.

引用

页码：31 / 34

页数：4

共 50 条

[31] Steroid administration in the Covid-19 era; timing does matter!
Petros V. Vlastarakos
Dimitrios Katsianos
European Archives of Oto-Rhino-Laryngology, 2021, 278 : 1293 - 1294
[32] Steroid administration in the Covid-19 era; timing does matter!
Vlastarakos, Petros V.
Katsianos, Dimitrios
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2021, 278 (04) : 1293 - 1294
[33] Tocilizumab for severe COVID-19 pneumonia
Mourad, Jean-Jacques
Azria, Philippe
LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E659
[34] Thromboinflammation response to tocilizumab in COVID-19
Gergi, Mansour
Cushman, Mary
Littenberg, Benjamin
Budd, Ralph C.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (08) : 1262 - 1268
[35] Response to "Tocilizumab therapy and COVID-19"
Bhargava, Pallavi
JOURNAL OF OSTEOPATHIC MEDICINE, 2021, 121 (11): : 867 - 868
[36] Audio Interview: Tocilizumab and Covid-19
Rubin, Eric J.
Baden, Lindsey R.
Morrissey, Stephen
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (17): : E114 - E114
[37] Effectiveness of tocilizumab in COVID-19 infection
Romero Puerto, Javier
Soria Martin, Alberto
Garcia Marin, Javier
Moreno Herrera, Adriana
Fages Perez, Marina
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1746 - 1747
[38] Tocilizumab for hospital patients with COVID-19
Afra, Kevin
Chen, Luke Y. C.
Sweet, David
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (26) : E1027 - E1028
[39] An EUA for Tocilizumab (Actemra) for COVID-19
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1629): : 113 - 114
[40] Rational use of tocilizumab in COVID-19
Jain, Siddharth
Sharma, Shefali Khanna
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (11)

← 1 2 3 4 5 →